IMMUNOPHENOTYPE AS PROGNOSTIC FACTOR FOR DIFFUSE LARGE B CELL LYMPHOMA IN PATIENTS UNDERGOING CLINICAL RISK ADAPTED THERAPY

VEELKEN, H., VIK DANNHEIM, S., SCHULTE MOENTING, J., MARTENS, U.M., FINKE, J., & SCHMITT GRAEFF, A.. (2007). IMMUNOPHENOTYPE AS PROGNOSTIC FACTOR FOR DIFFUSE LARGE B CELL LYMPHOMA IN PATIENTS UNDERGOING CLINICAL RISK ADAPTED THERAPY. ANNALS OF ONCOLOGY (OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY: ESMO), 18(5), 931-939. SID. https://sid.ir/paper/543203/en

VEELKEN H., VIK DANNHEIM S., SCHULTE MOENTING J., MARTENS U.M., FINKE J., SCHMITT GRAEFF A.. IMMUNOPHENOTYPE AS PROGNOSTIC FACTOR FOR DIFFUSE LARGE B CELL LYMPHOMA IN PATIENTS UNDERGOING CLINICAL RISK ADAPTED THERAPY. ANNALS OF ONCOLOGY (OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY: ESMO)[Internet]. 2007;18(5):931-939. Available from: https://sid.ir/paper/543203/en

H. VEELKEN, S. VIK DANNHEIM, J. SCHULTE MOENTING, U.M. MARTENS, J. FINKE, and A. SCHMITT GRAEFF, “IMMUNOPHENOTYPE AS PROGNOSTIC FACTOR FOR DIFFUSE LARGE B CELL LYMPHOMA IN PATIENTS UNDERGOING CLINICAL RISK ADAPTED THERAPY,” ANNALS OF ONCOLOGY (OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY: ESMO), vol. 18, no. 5, pp. 931–939, 2007, [Online]. Available: https://sid.ir/paper/543203/en